去纤苷的用药指南

Defibrotide is suitable for hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation. Since this drug has not yet been marketed in China and is not included in the medical insurance catalog, it is necessary to strictly follow the medication guidelines during clinical use. This article will introduce in detail the standard medication regimen of defibrotide, possible adverse reactions, and medication precautions for special groups, providing a reference for rational clinical medication use.

Defibrotide Medication Guide

The standardized use of defibrotide involves precise dosage calculation, strict administration methods and scientific treatment course management, and must be used under the guidance of a doctor.

Standard dosage regimen

The recommended dose for adult and pediatric patients is 6.25 mg/kg every 6 hours as an intravenous infusion over 2 hours. Dose calculations are based on baseline weight before the HSCT preparation protocol, not current weight. This dose design takes into account drug metabolism characteristics and VOD pathological mechanisms.

Administration method

Drugs must be diluted before infusion and filtered using a special infusion set. Continuous intravenous injection is used, and the infusion time is strictly controlled to 2 hours. Vital signs, especially changes in blood pressure, need to be monitored during the infusion.

Treatment management

The basic course of treatment is 21 days. If VOD symptoms are not completely relieved, it can be extended to 60 days. The efficacy evaluation should include multi-dimensional indicators such as liver function indicators, ascites resolution and renal function improvement.

Side effects of defibrotide

Multi-system adverse reactions may occur during defibrotide treatment, which requires close clinical monitoring.

Circulatory system reaction

Hypotension manifests as dizziness or postural hypotension, and minor bleeding events such as nosebleeds are related to the anti-thrombotic effect of the drug. Be alert to the risk of serious bleeding.

Digestive system discomfort

Symptoms such as diarrhea, nausea, and vomiting are mostly mild to moderate. They are usually noticeable in the early stages of medication and may lessen over time.

Allergic reactions

Although allergic reactions such as rashes and urticaria are uncommon, they may progress to severe allergic reactions. Special attention should be paid to skin manifestations and respiratory conditions in the early stage of medication.

Timely detection and treatment of these adverse reactions is of great significance to ensure the continuity of treatment.

Medication of defibrotide for special groups

Different groups of people have different metabolism and reactions to defibrotide, and individualized medication plans are required.

Use in pregnant women

Animal studies have shown that defibrotide may cause harm to the fetus. Pregnant women should only consider using it when the benefits clearly outweigh the risks, and they need to be fully informed of potential risks and closely monitored.

Breastfeeding women

The drug may be secreted through breast milk, causing a risk of bleeding in nursing infants. During treatment it is recommended to suspend breastfeeding until the drug is completely removed.

Pediatric patients

The safety and effectiveness of the drug in pediatric patients have been confirmed, and the dosage based on body weight is the same as that of adults. Special attention should be paid to the risk of hypotension and bleeding, and the frequency of monitoring should be strengthened.

Personalized medication plans for special groups can control the disease while reducing damage to the body.